Have a feature idea you'd love to see implemented?
Let us know!
ELVN Enliven Therapeutics Inc
Price (delayed)
$25.41
Market cap
$1.24B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$1.14B
Highlights
Enliven Therapeutics's EPS has surged by 59% YoY
The company's quick ratio fell by 21% YoY but it rose by 21% QoQ
ELVN's equity is up by 10% YoY but it is down by 5% QoQ
The company's net income fell by 38% YoY and by 2.9% QoQ
Key stats
What are the main financial stats of ELVN
Market
Valuations
Earnings
Shares outstanding
48.86M
Market cap
$1.24B
Enterprise value
$1.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$84.98M
EBITDA
-$84.35M
Free cash flow
-$68.53M
Per share
Balance sheet
Liquidity
EPS
-$1.89
Free cash flow per share
-$1.42
Book value per share
$6.11
Revenue per share
$0
TBVPS
$6.33
Total assets
$305.43M
Total liabilities
$17.03M
Debt
$0
Equity
$288.4M
Working capital
$279.97M
Debt to equity
0
Current ratio
17.44
Quick ratio
17.14
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.3%
Return on equity
-29.5%
Return on invested capital
-47.9%
Return on capital employed
-29.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELVN stock price
How has the Enliven Therapeutics stock price performed over time
Intraday
-0.08%
1 week
1.97%
1 month
-11.98%
1 year
128.1%
YTD
83.6%
QTD
-0.51%
Financial performance
How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.39M
Net income
-$85.21M
Gross margin
N/A
Net margin
N/A
Enliven Therapeutics's operating income has decreased by 41% YoY and by 2.9% QoQ
The company's net income fell by 38% YoY and by 2.9% QoQ
Growth
What is Enliven Therapeutics's growth rate over time
Valuation
What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
4.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enliven Therapeutics's EPS has surged by 59% YoY
ELVN's P/B is 73% above its 5-year quarterly average of 2.4 and 34% above its last 4 quarters average of 3.1
ELVN's equity is up by 10% YoY but it is down by 5% QoQ
Efficiency
How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital is up by 34% year-on-year but it is down by 3% since the previous quarter
The return on equity is up by 10% year-on-year
Enliven Therapeutics's ROA has decreased by 5% YoY
Dividends
What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELVN.
Financial health
How did Enliven Therapeutics financials performed over time
ELVN's total liabilities is up by 39% year-on-year but it is down by 23% since the previous quarter
The current ratio has contracted by 22% YoY but it has grown by 21% from the previous quarter
The debt is 100% less than the equity
ELVN's equity is up by 10% YoY but it is down by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.